With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is $50.92, with a 24-hour trading volume of $207.99M. The asset's market cap is $225.24B, after moving 2.53% in the last day.
Tokenized Novo Nordisk A/S is trading at $52.01, with a tokenized market cap of $36.87M and a 24-hour trading volume of $1.38M. The tokenized asset has moved 2.62% in the past 24 hours.